StockData
Polaryx Therapeutics, Inc. logo

Polaryx Therapeutics, Inc. (PLYX) company profile

PLYXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 6/30
$1.60−0.07 (-4.19%)

Close on Nov 17, 2026Market cap $79.75MP/E –Yield –

About Polaryx Therapeutics

Pharmaceutical Preparations, SIC 2834

Polaryx Therapeutics, Inc. is a clinical-stage biotechnology company that discovers and develops treatments for rare pediatric lysosomal storage disorders. Its therapeutic pipeline comprises oral small molecule candidates and gene therapies targeting underlying cellular dysfunction and neuroinflammation. The company's lead product candidate is PLX-200, a reformulated oral solution targeting neuronal ceroid lipofuscinosis subtypes CLN2 and CLN3, Krabbe disease, and Sandhoff disease. Other programs include PLX-300, a small molecule in preclinical evaluation, PLX-100, an oral combination therapy, and PLX-400, an early-stage gene therapy. The company operates in the lysosomal storage disorders segment, developing therapies primarily for pediatric patients diagnosed with fatal genetic metabolic conditions.

The company maintains its principal executive offices in Paramus, New Jersey, and operates as a Nevada corporation. Polaryx utilizes external partnerships and receives consulting support across development functions from a team of eleven specialists based at its controlling shareholder in Hong Kong.

Summary of the business section of Polaryx Therapeutics's latest annual report, written by StockData.

Company profile

Company

Legal name
Polaryx Therapeutics, Inc.
Founded
2014
Headquarters
Paramus, NJ
Address
140 East Ridgewood Avenue, Suite 415, South Tower 07652
Phone
(201) 940-7236
Employees
11, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
WY
Fiscal year ends
December 31
Auditor
GRANT THORNTON LLP, Edison, New Jersey

Stock & identifiers

Ticker
PLYX
Exchange
Nasdaq
IPO date
Feb 2, 2026
Shares outstanding
50M, Jul 31, 2026
Filer category
<br>Emerging growth company
SEC CIK
2075320
CUSIP
73110F100
ISIN
US73110F1003
FIGI
BBG01ZPFWW22
Share class FIGI
BBG01ZPFWWC1
LEI
529900HOCSZB5SQ6D467
EIN
00-0000000

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Alex Keun Mo YangChief Executive Officer, Director–
G. Michael LandisChief Financial Officer, Director228,225
Lisa BollingerChief Medical Officer150,358
Andrew John OChief Investment Officer471,808
Partners Healthcare Ltd MstoneDirector25,633,249
III Francis A. BraunDirector–
Mitchel BergerDirector–
Charles S. RyanDirector–

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryStock awardsTotalvs. prior year
Alex Yang
Chief Executive Officer
–$792.00K$792.00K+37%
Lisa Bollinger
Chief Medical Officer*
$62.50K$420.00K$482.50K–
G. Michael Landis
Chief Financial Officer
$46.67K$264.00K$310.67K+257%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Feb 2, 2026
Securities offered
47,343,297
Exchange
Nasdaq
First trading day
Feb 2, 2026
First-day close
$35.00
Lock-up ends (est.)
Aug 1, 2026

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Corporate history

Events identified from SEC filings

See a number that looks wrong?